🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

206 results for “Glaxo” Clear

  1. GSK3196165 Dose 1

    GlaxoSmithKline

    Arthritis, Rheumatoid

    phase 2 small molecule completed

    1 trial

  2. GSK4527226

    GlaxoSmithKline

    Alzheimer's Disease

    phase 2 small molecule active

    1 trial

  3. GSK962040 50 mg

    GlaxoSmithKline

    Gastroparesis

    phase 2 small molecule terminated

    2 trials

  4. GW679769

    GlaxoSmithKline

    Postoperative Nausea and Vomiting

    phase 2 small molecule completed

    1 trial

  5. Isatuximab, Dexa-ratiopharm® 8 mg Injektionslösung, Fortecortin® 2 mg Tabletten, Revlimid 15 mg hard capsules, Zelvina 2.5 mg hard capsules, Revlimid 10 mg hard capsules, Revlimid 2.5 mg hard capsules, Zelvina 5 mg hard capsules, Zelvina 25 mg hard capsules, Imnovid 2 mg hard capsules, Imnovid 3 mg hard capsules, Zelvina 10 mg hard capsules, Revlimid 25 mg hard capsules, Imnovid 1 mg hard capsules, Dexamethason 8 mg GALEN® Tabletten, Nirogacestat, Isatuximab, Nirogacestat, Dexa 8 mg inject JENAPHARM Injekti

    GlaxoSmithKline

    Multiple Myeloma

    phase 2 small molecule active

    1 trial

  6. JEMPERLI 500 mg concentrate for solution for infusion

    GlaxoSmithKline

    Relapsed/Refractory Tumors

    phase 2 small molecule active

    1 trial

  7. JEMPERLI 500 mg concentrate for solution for infusion

    GlaxoSmithKline

    Neoplasms, Head and Neck

    phase 2 small molecule active

    1 trial

  8. JEMPERLI 500 mg concentrate for solution for infusion

    GlaxoSmithKline

    Neoplasms, Colorectal

    phase 2 small molecule active

    1 trial

  9. JEMPERLI 500 mg concentrate for solution for infusion

    GlaxoSmithKline

    Neoplasms, Rectal

    phase 2 small molecule active

    1 trial

  10. JEMPERLI 500 mg concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion

    GlaxoSmithKline

    Lung Cancer, Non-Small Cell

    phase 2 small molecule active

    1 trial

  11. Locally Sourced 0.9% Sodium Chloride

    GlaxoSmithKline

    Dermatitis, Atopic

    phase 2 small molecule active

    1 trial

  12. Locally Sourced 0.9% Sodium Chloride

    GlaxoSmithKline

    Dermatitis, Atopic

    phase 2 small molecule active

    1 trial

  13. NaCl 0.9% solution

    GlaxoSmithKline

    Meningitis, Meningococcal

    phase 2 small molecule active

    1 trial

  14. NaCl solution

    GlaxoSmithKline

    Herpes Simplex

    phase 2 small molecule active

    1 trial

  15. Nimenrix powder and solvent for solution for injection in pre-filled syringe Meningococcal groups A, C, W-135 and Y conjugate vaccine, Prevenar 13 suspension for injection pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed), Rotarix oral suspension in pre-filled oral applicator Rotavirus vaccine, live, Infanrix hexa, Powder and suspension for suspension for injection. Diphtheria (D), tetanus (T), pertussis (acellular, component) (Pa), hepatitis B (rDNA) (HBV), poliomyelitis (inactivated) (IP

    GlaxoSmithKline

    Infections, Meningococcal

    phase 2 small molecule active

    1 trial

  16. Other: Placebo

    GlaxoSmithKline

    Menopausal and Female Climacteric States

    phase 2 small molecule completed

    1 trial

  17. POMALIDOMIDE, POMALIDOMIDE, DEXAMETHASONE, CARFILZOMIB, BORTEZOMIB, POMALIDOMIDE, CARFILZOMIB, POMALIDOMIDE, CARFILZOMIB, DEXAMETHASONE

    GlaxoSmithKline

    Relapsed or Refractory Multiple Myeloma

    phase 2 small molecule active

    1 trial

  18. Pemetrexed Pfizer 25 mg/ml concentrate for solution for infusion., KEYTRUDA 25 mg/mL concentrate for solution for infusion, Carboplatin-Teva 10 mg/ml Concentrate for Solution for Infusion, Cisplatin 1 mg/ml Concentrate for Solution for Infusion, Pemetrexed Pfizer 100 mg powder for concentrate for solution for infusion, JEMPERLI 500 mg concentrate for solution for infusion, Pemetrexed Pfizer 25 mg/ml concentrate for solution for infusion., Pemetrexed Pfizer 25 mg/ml concentrate for solution for infusion.

    GlaxoSmithKline

    Lung Cancer, Non-Small Cell

    phase 2 small molecule active

    1 trial

  19. Placebo for Bepirovirsen Solution for Injection, 150 mg/mL SSD

    GlaxoSmithKline

    Hepatitis B

    phase 2 small molecule active

    1 trial

  20. Placebo for GSK5784283.

    GlaxoSmithKline

    Asthma

    phase 2 small molecule active

    1 trial

  21. Placebo to Match GSK3915393 Tablet

    GlaxoSmithKline

    Idiopathic Pulmonary Fibrosis

    phase 2 small molecule active

    1 trial

  22. Placebo to Match GSK3965193 Tablets

    GlaxoSmithKline

    Hepatitis B

    phase 2 small molecule active

    1 trial

  23. Reblozyl 75 mg powder for solution for injection

    GlaxoSmithKline

    Myelofibrosis

    phase 2 small molecule active

    1 trial

  24. Rotarix™

    GlaxoSmithKline

    Infections, Rotavirus

    phase 2 mab completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources